GENERAL COMMENTS
Thank you for asking me to review this manuscript. The Authors aim to evaluate the risk of bias (ROB) among RCT referenced in the 2015 AHA.
I have a few questions/comments regarding the reporting of the methodological approach, which is not always clear from the manuscripts.
Abstract: 1. Line 17, please not use "etc".
Introduction: 2. It could be interesting for readers to give references of the AHA guidelines and ECC used for the analysis. 3. Please not use the term "etc" in line 23. 4. The introduction is well structured but i think authors could more develop the risk for patients when we based guidelines on biased studies.
Methods 5. Line 51, authors should moderate their explanation about allocation and blinding in simulation and education studies. In fact, some studies explained how the blinding could be perform in these cases (Philippon AL, Bokobza J, Bloom B et al (2016) Effect of simulated patient death on emergency worker's anxiety: a cluster randomized trial. Ann Intensive Care 6(1):60; Kahan BC, Cro S, Doré CJ et al (2014) Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials 15:456, Chauvin A, Truchot J, Befata A et al (2018) Randomized controlled trials of simulation-based interventions in Emergency Medicine: a methodological review. Intern Emerg Med 13(3):433). 6. Line 20: please give initials of the two reviewers and the third. 7. Please justify why you examines the ROB for six differents domains. this could be help the reader.
Thank you for the opportunity to review this submission.
General comments:
This manuscript aims to identify the risk of bias of RCTs referenced in the 2015 American Heart Association (AHA) guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. For that purpose, the Cochrane Collaboration's tool for assessing risk of bias in randomized trials was used by the authors.
The AHA guidelines for cardiopulmonary resuscitation are nowadays recognized as the world's most authoritative resuscitation guidelines. Assessing bias of RCTs referenced in these guidelines is therefore of paramount importance. The research question is appropriate and well stated. Choosing the Cochrane Collaboration's tool seems also appropriate since this tool has become the standard approach to assess risk of bias in randomized clinical trials.
However, I have several comments about some of the assertions in the manuscript.
Major comments:
1) The statement that the proportion of RCTs at unclear or high risk of bias was high in the 2015 AHA guidelines (page 2 line 43-45 and page 13 lines 27) has to be reformulated to more objectively reflect the principal results of the study and to avoid confusion for your readers. First, in the majority of domains (5 out of 6 domains), only small rather than high proportions of trials were shown to be associated with high risk of bias (between 5.4 and 0.6%). Second, to avoid summarizing all outcomes at once, authors should also state that unclear risk of bias was especially high in the Blinding of outcome assessment domain, but to a lesser extent in the other domains.
2) Jørgensen et al. have shown that the judgement of at least one risk of bias domain as "unclear" was found in 89 % of RCTs when using the Cochrane's tool for assessing risk of bias (PMID: 27160280) . This large proportion is a considerable problem for the interpretation of the results. Jørgensen et al. argued that in many cases the uncertainty can be resolved by contacting trial authors or by searching publicly available trial registers. Because uncertainty was elevated in the present study, did the authors tried to resolve it by contacting the trial authors or by searching trial registers? If not, this should be discussed as a limitation of the study.
3) The authors state that 2 independent reviewers scored the RCTs and a third reviewer resolved disagreements. They clearly established in Appendix 1 a detailed protocol for evaluation in order to reduce disagreements between them. But how was consistency of assessment between both reviewers evaluated? Was a κ (kappa) value calculated for each of the six Cochrane domains? This information is lacking in the Methods section. This information is nevertheless essential since differences in the appraisal and interpretation of risk of bias across trials can lead to variation in the interpretation of results of RCTs, and ultimately impact the conclusions and clinical practice. The inter-rater agreement for the individual domains of the Cochrane Collaboration's tool has been described to vary widely, ranging from slight (κ=0.13) to substantial (κ=0.74) (PMID: 24824199). It would be interesting to evaluate the inter-rater disagreement in this study. Disagreement seems to occur when terminology is used inconsistently (e.g. for blinding), when judgements are based on insufficient information or when interventions are more complex, such as those referenced in AHA guidelines (e.g. in non-drug trials). In addition, reviewers often encounter problems when assessing the domains "incomplete outcome data" and "selective outcome reporting" (PMID: 27160280). Please clarify.
4) The authors mention that they excluded simulation-based or educational studies from their search because allocation concealment and blinding of participants and personnel are inevitably impossible in these studies (page 4 lines [51] [52] [53] . This assertion appears over-interpreted and possibly wrong to me. As recently shown by Chauvin et al. (PMID: 29147942) , among 270 RCTS identified in the field of emergency medicine and cited in the top 10 emergency medicine journals, about 25% assessed simulation-based medical education. Among them, random sequence generation and allocation concealment were performed correctly in 66% and 49%, whereas blinding of participants and personnel was performed correctly in 19 and 68% respectively. Furthermore, in the Simulation-Based Research extensions for the Consolidated Standards of Reporting Trials (CONSORT) statements developed by Cheng et al. (PMID: 27465839) , the items 9 and 11 clearly advocate to describe allocation concealment mechanism and blinding in simulation-based studies. Hence, the authors should either add the previously excluded studies in their manuscript (but it would be a major change) or they have to modify their sentence lines 51-53 and argue more adequately in the Methods section why they choose not to include these studies. This could be also described as a limitation of the study.
The authors also mention that they excluded crossover studies because of the impossibility to randomize adequately individuals in these studies (page 4 lines 53-55). While designing crossover studies with appropriate randomization seems indeed very complicated during resuscitation in real life, this assumption should be tempered somewhat by the fact that randomization in crossover trials involving simulated resuscitation events is largely feasible. Several studies have demonstrated the benefit of simulation as an investigative research methodology to answer research questions that otherwise could not be answered during resuscitation.
5) I also wonder why the authors decided to identify journal's IFs in 2015 (the date of publication of the AHA guidelines update) rather than respective years of publication for each RCT. Indeed, because the authors thereafter determine the risk of bias for each of six Cochrane domains according to three IF groups (IF<5, 5≤IF<10, and IF≥10) as if they were published in 2015 in Figure 1 -and the weight of bias reported by RCTs' IF could be over-or underestimated if they are all reported as if published in 2015 instead of respective years of publication. The rationale given in the Limitation section is insufficient.
6) The authors do not explain the reason why they choose to categorize the type of intervention of non-drug trials in Device, Reperfusion, Oxygen, Hypothermia, and Prevention of hypothermia (Table 1) . Was this choice arbitrarily? Are these items more biologically relevant than hands-off time, no-flow time or endotracheal intubation versus bag-mask ventilation for example? It would be important for the authors to clarify this point, as this might appear important for your readers.
7) The authors mention in the Results section that two thirds of the RCTs (65.1%, 108/66) Figure 6 ). Do the authors believe that this trend has something to do with the reverse trend of an increasing number of RCTs during the same period, paralleling an increase in quality of trial reporting?
11) Importantly, given that the authors are interested in the evolution of the risk of bias over the years between 1980 and 2015, and knowing the huge improvement brought by the CONSORT statement introduced in 1996 to improve the quality of reporting of RCTs, it would be wise to add a figure showing the evolution of risk of bias for each of the six domains of Cochrane's Tool before and after the introduction of the CONSORT statement in 1996 and after its update in 2010. This point can then be linked with the paragraph discussing the CONSORT statement on page 12.
Minor points:
1) The authors must discuss why they did not used the "other bias" domain of the Cochrane Collaboration's tool.
2) Page 4 line 43: the authors should cite the 2015 AHA guidelines update for CPR and ECC as references. Because these guidelines are divided into 15 Parts that were used for this cross-sectional review, I recommend citing them all (ie 15 references).
3) Page 6 line 18: replace 78.9% (93/766) by 78.9% (131/166). Figure 4 accordingly by including both missing RCTs.
4)

7)
In my opinion, the wording " […] and was higher than that in previous studies" (page 10 lines 7-8) is awkward because these "previous studies" have nothing to do with the current study as they do not relate to AHA guidelines. I would recommend removing this wording.
8) Page 10 line 11: The value "79.7%" is wrong. Please replace it by 77.7%.
9) As no statistical tests were undergone in this study, I suggest removing the word "significantly", page 9 line 32 and page 10 line 17.
10) Page 10 line 25: remove the wording "(30%)" as it does not bring supplemental information.
11) Page 10 line 25, the authors first describe the high proportion of trials with unclear risk of bias in random sequence allocation generation and second in blinding of outcome measurements. Then, they discuss both items in a different order, starting with a paragraph on blinding outcome (lines 27 to 46) before a second paragraph on random sequence generation (page 10 lines to page 11 line 7). I recommend reordering both paragraphs to avoid confusion for your readers.
12) Page 12 line 39: remove the additional space between "the" and "items". Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care" between "…bias" and "in each…"
VERSION 1 -AUTHOR RESPONSE
Reviewer #1
Thank you for your detailed and rigorous comments. We considered again all of your comments and the responses are listed below.
Sincerely and best regards.
Responses to specific points blinding of participants. The assessment of the risk of bias for the blinding of outcome assessment is also possible for education studies. Therefore, we additionally analyzed the risk of bias for simulation and education studies after including these studies.
Point
The analysis was repeated after including cluster RCTs and crossover RCTs. These studies may experience problems with allocation concealment, but random sequence generation or blinding can be performed appropriately. We revised the manuscript accordingly.
In addition, we revised some criteria for judging the risk of bias. We judged the domain of blinding of participants and personnel as a low risk of bias even when the participants and personnel were blinded to the study objectives. For the domain of blinding of outcome assessment, we also assessed that domain as low risk when the study endpoint was objective or permanent, such as mortality or laboratory findings, which were unlikely to affect the bias even if the outcome assessors were not blinded. We added these points to supplementary appendix 1. Using the revised criteria, the manuscript was revised according to the re-evaluation of the blinding of participants and personnel and blinding of outcome assessment. RCTs in letter format were also excluded.
We included clinical studies in which participants were human patients and excluded animal studies. Studies that analyzed existing
RCTs and RCTs published in a letter format were also excluded.
Before revision After revision
We examined the risk of bias in RCTs by grouping them into six topics ( 
Point 6
Methods: Line 20: please give initials of the two reviewers and the third.
Answer Thank you for your suggestion. We added the initials of the two reviewers and the third reviewer who scored the RCT articles.
Before revision After revision
Two independent reviewers scored the RCT articles in each domain, and a third reviewer resolved the discrepancies.
Two independent reviewers (Y.C. and C.K.)
scored the RCT articles in each domain, and a third reviewer (B.K.) resolved the discrepancies.
Point 7
Methods: Please justify why you examines the ROB for six differents domains. this could be help the reader.
Answer
The following six domains of the Cochrane Collaboration tool were selected to evaluate the risk of bias: random sequence generation and allocation concealment for selection bias, blinding of participants and personnel for performance bias, blinding of outcome assessment for detection bias, incomplete outcome data for attrition bias, and selective reporting for reporting bias. Other types of bias can be specified to measure the bias that is not measured in the domains described above. However, since this study confirmed the bias in the RCTs examining the various topics included in the guidelines, we were unable to simply define the other sources of bias. Therefore, in this study, six domains, except for other types of bias, were selected and analyzed. We outcome data for attrition bias, and selective reporting for reporting bias. We did not prespecify the other bias that are not identified by the above six domains described above, because we were not able to simply define the other bias in
RCTs of various topics included in the guidelines.
Point 8
Methods: Line 36, could you justify why you used IF 5 to determine low or high impact factor? In fact, we know that the level of IF is different among medical speciality and so a same IF score could not reflect the same "quality".
Answer Yes, I agree that the level of IF is different among various medical categories. We divided the IF into three groups (≥10, 5-10, and <5) based on a previous study.
[1] The authors divided the IF into four groups (≥10, 5-10, <5 and no IF), but we divided the IF into three groups because few journals did not have an IF in our study. We did not designate the journals with an IF less than 5 as a low quality journal. As you suggested, many journals are located in the top level in specialist categories, although their impact factors are less than five. Additionally, the IF may not accurately reflect the quality of each journal. We were not trying to express whether the journal had high or low quality, but simply whether the impact factor is high or low. We only wanted to investigate the differences in each type of bias according to the level of IF, not the quality of each journal, because a comparison of the quality using IF among journals in different categories is impossible. We replaced the words (high, relatively high, and low) with 
Point 10
Results: Please add a flow chart.
Answer
We added a flow chart to supplementary appendix 2.
Before revision After revision
After 137 articles were excluded, a total of 166 RCTs were selected for analyses. Studies were excluded because they were animal trials (n=25), simulation or education studies (n=97),
cluster RCTs (n=10), crossover studies (n=8), trials that analyzed existing RCTs (n=3), and RCTs in a letter format (n=1).
After the exclusion of 27 articles, 273 RCTs were selected for analyses. Studies were excluded because they were animal studies (n=23), studies that analyzed existing RCTs (n=3), and RCTs published in a letter format (n=1) (supplementary appendix 2, 3).
Point 11
Results: I think it is important to report references excluded from the analysis in the appendix with reasons. This could help for the transparency.
Answe r
We added a list of references excluded from the analysis to supplementary appendix 3 along with the reasons for exclusion.
Supplementary appendix 3. References excluded from the analysis. 
Point 14
Results: The ROB could be only analyzed if we have the outcome. In fact, in emergency situation using a placebo could be not available if, for example, the outcome is the death at 30 minutes after the advance resuscitation. But if the outcome is quality of the massage using vs not using a device: the blinding must be performed. So, authors must be gave outcome of RCT included in the analysis.
This must more be discuss in the discussion section.
Answer Thank you for your comments. As you suggested, the outcome is important for assessing the risk of bias. Therefore, we added all the primary outcomes of RCTs included in this study to the supplementary appendix 4. In our study, 78.8% of RCTs showed a high risk of bias in the blinding of participants and personnel, presumably because the type of intervention is a non-drug trial that cannot be blinded. Additionally, as you suggested, blinding is not possible in some cases because of the ethical issue depending on the outcome. We added this point to the Discussion section.
The blinding of outcome assessment is also affected by the outcome definition. Even if the blinding of outcome assessment is not properly implemented, the risk of bias for objective outcomes is very low. Moreover, when the blinding of outcome assessment is impossible, the possibility of bias can be reduced by modifying the outcome definition.
We therefore reassessed the included RCTs by revising the criteria for the blinding of outcome assessment.
Before revision After revision
Furthermore, in some cases, blinding is not performed because of an ethical issue, depending on the outcome of cardiac arrest. 
Point 15
Other: Please, report this review in accordance with the Preferred Reporting of Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement. And give the checklist in Appendix 1.
Answer
We completed PRISMA checklist instead of PRISMA-P, which is for study protocols, according to the editor's recommendations. Thank you for your suggestion.
Reviewer #2
Sincerely and best regard.
Answers for major comments
Major point 1
The statement that the proportion of RCTs at unclear or high risk of bias was high in 
Major point 3
The authors state that 2 independent reviewers scored the RCTs and a third reviewer (PMID: 27465839), the items 9 and 11 clearly advocate to describe allocation concealment mechanism and blinding in simulation-based studies. Hence, the authors should either add the previously excluded studies in their manuscript (but it would be a major change) or they have to modify their sentence lines 51-53 and argue more adequately in the Methods section why they choose not to include these studies. This could be also described as a limitation of the study.
The authors also mention that they excluded crossover studies because of the impossibility to randomize adequately individuals in these studies (page 4 lines 53-55).
While designing crossover studies with appropriate randomization seems indeed very complicated during resuscitation in real life, this assumption should be tempered somewhat by the fact that randomization in crossover trials involving simulated resuscitation events is largely feasible. Several studies have demonstrated the benefit of simulation as an investigative research methodology to answer research questions that otherwise could not be answered during resuscitation. The analysis was repeated after including cluster RCTs and crossover RCTs. Cluster
RCTs and crossover RCTs may experience problems with allocation concealment, but random sequence generation or blinding can be performed appropriately.
In summary, we analyzed the risk of bias by including simulation and education studies, cluster RCTs, and crossover RCTs, and we revised the manuscript accordingly. In addition, if participants and personnel do not know the study objectives, the study is judged as having a low risk of bias and we added this point to supplementary appendix 1. Criteria for judging the risk of bias. For objective end-points such as such as mortality or laboratory data, a low risk of bias exists when the outcome assessor is not blinded. The evaluation criteria listed in supplementary appendix 1 were modified to score the blinding of outcome assessment as low risk for the studies reporting objective outcomes. Using the revised criteria, the manuscript was revised after a re-evaluation of the blinding of participants and personnel and blinding of outcome assessment in all included studies.
The following text has been added to the Methods section: If participants do not know the study objectives, the domain of blinding of participants and personnel was judged as a low risk of bias. In addition, studies with objective/permanent end-points, such as mortality or laboratory data, were evaluated as having a low risk of bias for the blinding of outcome assessment. 
Major point 6
The authors do not explain the reason why they choose to categorize the type of intervention of non-drug trials in Device, Reperfusion, Oxygen, Hypothermia, and Prevention of hypothermia (Table 1) . Was this choice arbitrarily? Are these items more biologically relevant than hands-off time, no-flow time or endotracheal intubation versus bag-mask ventilation for example? It would be important for the authors to clarify this point, as this might appear important for your readers.
Answer Thank you for your comments. Device, Reperfusion, Oxygen, Hypothermia, and Prevention of hypothermia were arbitrarily divided. We analyzed the risk of bias in drug trials and non-drug trials, and these subcategories were added unnecessarily. The addition of these subcategories may confuse the reader; thus, we removed them from the manuscript and Table 2 . We only divided the trials into two groups (drug trials or non-drug trials).
Major point 7
The authors mention in the Results section that two thirds of the RCTs (65.1%, 108/166) included in the study had been published in journals with an IF≥5, and 41%
(68/166) had been published in journals with an IF greater than 10 (lines 25-30).
However, these values do not correspond to those shown in 
Major point 8
The authors state in the Results section that they excluded the random sequence Answer Yes, I agree that the level of IFs is different among various medical categories. We divided the IFs into three groups (≥10, 5-10, and <5) based on a previous study [1] . The authors divided the IFs into four groups (≥10, 5-10, <5 and no IF), but we divided the values into three groups because few journals lacked an IF in our study. We did not designate the journals with an IF less than 5 as low quality journals. As you suggested, many journals are located in the top level in specialist categories, although their impact factors are less than five. Moreover, the IF does not accurately reflect the quality of each journal. We were not trying to express whether the journal was of high or low quality, but only whether the IF was high or low. We only wanted to investigate the differences in the risk of each type of bias according to the level of IF, not the quality of each journal, because a comparison of quality using IFs among different categories is impossible. We revised this section after re-analyzing and interpreting the data from the newly included RCTs. Moreover, we discussed the limitations of using IFs in the Discussion section. Furthermore, we analyzed the risk of bias based on the year of introduction and update of the CONSORT statement as you recommended in major points 10 and 11. We revised the Abstract and Conclusions section based on the results from the new analysis. (Table 2) . Additionally, the IFs of device, oxygen therapy, and prevention of hypothermia were lower than those of other interventions (drug, reperfusion, and hypothermia). This suggests that RCTs with low impact factors lack information with which to evaluate bias.
The sentences were deleted.
Major point 10
Random sequence generation, incomplete outcome data, selective reporting and to a lesser extent allocation concealment show a decreasing trend of bias over years between 1980 and 2015 (page 9 lines 43-49, and Figure 6 ). Do the authors believe that this trend has something to do with the reverse trend of an increasing number of RCTs during the same period, paralleling an increase in quality of trial reporting?
Major point 11
Importantly, given that the authors are interested in the evolution of the risk of bias over the years between 1980 and 2015, and knowing the huge improvement brought by the CONSORT statement introduced in 1996 to improve the quality of reporting of RCTs, it would be wise to add a figure showing the evolution of risk of bias for each of the six domains of Cochrane's Tool before and after the introduction of the CONSORT statement in 1996 and after its update in 2010. This point can then be linked with the paragraph discussing the CONSORT statement on page 12.
Answer
Thank you for your suggestions. I agree with them. Figure 6 shows the proportions of trials with unclear and high risks of bias stratified into 5-year intervals. We divided the RCTs into 3 groups (≤1995, 1996-2009, and ≥2010) based on the year of introduction and update of the CONSORT statement, and re-analyzed the data and changed Figure   6 accordingly. We also showed both the proportions of RCTs with an unclear or high risk of bias and the proportion of RCTs with low, unclear, and high risks of bias. In addition, we revised the manuscript as described below.
Before revision After revision Figure 6 shows the percentage of RCTs at unclear or high risk of bias in 5-year increments.
Random sequence generation, incomplete outcome data, and selective reporting showed a decreasing tendency; however, the two domains on blinding did not show a decreasing tendency.
Allocation concealment showed a decreasing tendency, but it also increased slightly in 2011-
2015.
After stratification by the year of introduction (1996) (10/115) in ≥2010.
Answers for minor points
Minor point 1
The authors must discuss why they did not used the "other bias" domain of the Cochrane Collaboration's tool.
Answer
Other bias is the designation used to specify and measure the types of bias that are not measured in the six domains. However, since this study confirmed the bias of the RCTs in the various topics included in the guidelines, we were unable to simply define the other sources of bias. Therefore, in this study, six domains, except for other sources of bias, were selected and analyzed. We have added this information to the Methods section of the manuscript. This approach is consistent with previous studies. Table 2 in the order of n (%), IF.
Minor point 6
Figure 4 
Minor point 7
Answer Thank you for your comments. We removed "previous studies" as you recommended and revised the sentence.
Before revision After revision
We found that the proportion of trials at high risk of bias (inadequate methods) was high for the blinding of participants and personnel (72.9%) and was higher than that in previous studies.
The largest proportion of trials with a high risk of bias (inadequate methods) was observed for the blinding of participants and personnel (78.8%).
Minor point 8
Page 10 line 11: The value "79.7%" is wrong. Please replace it by 77.7%.
Answer
Thank you for your comments. The value of 79.7% was incorrect. The value was changed to 86.4% according to the results of the new analysis including 273 RCTs.
Before revision After revision
The remaining 79.7% of the RCTs were nondrug trials that could not use placebos.
The remaining 86.4% of the RCTs were nondrug trials that could not use placebos.
Minor point 9
As no statistical tests were undergone in this study, I suggest removing the word "significantly", page 9 line 32 and page 10 line 17. (Figure 4 ).
Minor point 10
Page 10 line 25: remove the wording "(30%)" as it does not bring supplemental information.
Answer
Thank you for your comments. I agree with your suggestion that the wording "(30%)"
should be removed as it does not provide supplemental information. We removed this text and revised the sentence according to the results of the new analysis including 273
RCTs.
Before revision After revision
However, there was a high proportion of trials with unclear risk of bias (>30%) in random sequence generation (33.7%) and blinding of outcome assessment (45.2%), which indicates that many trials did not sufficiently report the risk of bias.
However, greater than one-third of trials exhibited an unclear risk of bias for random sequence generation (38.5%) and allocation concealment (34.1%), indicating that many trials did not sufficiently report the risk of bias.
Minor point 11
Page 10 line 25, the authors first describe the high proportion of trials with unclear risk of bias in random sequence allocation generation and second in blinding of outcome measurements. Then, they discuss both items in a different order, starting with a paragraph on blinding outcome (lines 27 to 46) before a second paragraph on random sequence generation (page 10 lines to page 11 line 7). I recommend reordering both paragraphs to avoid confusion for your readers.
Answer
Thank you for your comments. I agree with your suggestion that the order of the text is somewhat confusing. We rearranged the order of the Discussion and revised the manuscript according to the results of the new analysis including 273 RCTs.
Minor point 12
Page 12 line 39: remove the additional space between "the" and "items".
Answer
Thank you for your comments. We revised the text. Thank you for your kind and careful comments. We tried our best to revise the manuscript according to these comments that helped us correct our errors and enhance the quality of the manuscript.
Point 1
In the Results paragraph of the Abstract section, the first and second sentences might be confusing for your readers. I recommend rephrasing: "Of these RCTs, 78.8% had a high risk of bias for blinding of participants and personnel, mostly (87.7%) non-drug trials".
Response
Thank you for your opinion. We revised the sentence as you commented as follows.
Before revision After revision
Of these RCTs, 78.8% had a high risk of bias for blinding of participants and personnel.
Of these RCTs, 78.8% had a high risk of bias for blinding of participants and personnel, mostly (87.7%) non-drug trials".
Point 2
Abstract section, line 34, I suggest replacing "poor reporting" by "unclear risk of bias".
Response
Thank you for your comments. In the Abstract, the phrase "poor reporting" has been corrected to "unclear risk of bias". There was a possibility that it was not easy for the readers to understand "poor reporting". Thank you for pointing out this issue.
Before revision After revision
The proportion of RCTs with poor reporting was higher for random sequence generation (38.5%) and allocation concealment (34.1%) than in other domains.
The proportions of RCTs with an unclear risk of bias were higher for random sequence generation (38.5%) and allocation concealment (34.1%) than in other domains.
Point 3
Abstract section, line 37, and Conclusion section line 16, the authors state "This proportion was reduced after…". But I believe that the proportion to which it refers (38.5% for the random sequence generation and 34.1% for allocation concealment) concern all published RCTs during the full period of analysis (Figure 2 ), whereas the fall to 31.3% and 32.2% concern only the proportion of RCTs conducted after 2010.
Would it not be more appropriate to describe the decrease from 65.4% before CONSORT to 31.3% after CONSORT for the random sequence generation and from 57.7% to 32.2% for the allocation concealment? The term "This proportion was reduced…" as used in the present manuscript does not seem adequate to me.
Response
Thank you for your comments. You have given thoughtful feedback, and I have been able to improve this passage as follows. We also added this sentence to the last paragraph of the Results section. 
Point 4
In Methods section, page 77, line 25, remove "above" before "six domains described above".
Response
Thank you for your comments. In this sentence, "above" was duplicated; I removed one of the duplicates. Thank you again for your careful review.
Before revision After revision
We did not pre-specify the other bias that are not identified by the above six domains described above, because we were not able to simply define the other bias in RCTs of various topics included in the guidelines.
We did not pre-specify the other sources of bias that are not identified by the above six domains described because we were not able to simply define the other sources of bias in RCTs of various topics included in the guidelines.
Point 5
In Discussion section, page 86, lines 21-25, I suggest rephrasing: " The kappa values for the Cochrane tool used in our study were greater than those observed when this tool was used in physical therapy trials [36] and similar than those found in quality reporting of five leading…"
Response
Thank you for your suggestion. I was able to improve the sentence with a more accurate expression according to your opinion.
Before revision After revision
The kappa values for the Cochrane tool used in our study were greater than physical therapy
The kappa values for the Cochrane tool used in our study were greater than those observed , based on Table 2 (upper part), but both calculated according to IFs at the date of publication.
Response
Thank you for your comments. We added a supplementary figure after stratification according to the IFs of the year of publication. We also revised the upper part of 
Thank you for your comments. We replaced "poor reporting" with "unclear risk of bias" in the Conclusions section, as you suggested.
Before revision After revision
The proportion of RCTs with poor reporting was high for random sequence generation and allocation concealment.
The proportions of RCTs with an unclear risk of bias were high for random sequence generation and allocation concealment.
